Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12371954 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| SCHEMBL12903081 | 1.00 | LMNA (0.31) | LMNAMAPTHTT | |
| SCHEMBL25050617 | 0.85 | — | — | |
| SCHEMBL24410958 | 0.85 | — | — | |
| SCHEMBL24410797 | 0.85 | — | — | |
| SCHEMBL24410795 | 0.85 | — | — | |
| SCHEMBL24410794 | 0.85 | — | — | |
| SCHEMBL22062797 | 0.82 | — | — | |
| SCHEMBL19491922 | 0.81 | — | — | |
| SCHEMBL24330287 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240067662-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-02-29 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760744-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3535260-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2023-08-30 | — | — | EP | disclosed |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | SHANGHAI ZHEYE BIOTECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | Hepagene Therapeutics (HK) Limited (HK) | 2021-02-16 | — | — | US | disclosed |
| US-20200181118-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | Hepagene Therapeutics (HK) Limited (HK) | 2019-09-12 | — | — | US | disclosed |
| US-10239849-B2 | Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. | 2019-03-26 | — | — | US | disclosed |
| US-8404687-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-08-04 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | LMNA 3201/4885MAPT 1885/4885HTT 860/4885 |
| US-20190276465-A1 | Nitrogen-Containing Heterocyclic Compounds As FXR Modulators | NR1H4, FXR1, FXR2 | LMNA 3466/4885MAPT 3342/4885HTT 644/4885 |
| US-10239849-B2 | Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, ADRB1 | LMNA 1225/4885MAPT 1371/4885HTT 3208/4885 |
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | LMNA 2419/4885MAPT 607/4885HTT 963/4885 |
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | LMNA 3067/4885MAPT 4126/4885HTT 3758/4885 |
| US-11760744-B2 | Fused ring compounds | KRAS, NRAS, HRAS | LMNA 3608/4885MAPT 3269/4885HTT 3961/4885 |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | LMNA 4309/4885MAPT 4070/4885HTT 2918/4885 |
| US-10919903-B2 | Nitrogen-containing heterocyclic compounds as FXR modulators | NR1H4, FXR1, FXR2 | LMNA 3466/4885MAPT 3342/4885HTT 644/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | LMNA 2374/4885MAPT 532/4885HTT 3349/4885 |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | LMNA 4858/4885MAPT 3122/4885HTT 1781/4885 |
| US-10450286-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | LMNA 217/4885MAPT 3053/4885HTT 708/4885 |
| US-20230159529-A1 | AROMATIC COMPOUND AND APPLICATION THEREOF IN ANTITUMOR DRUG | TYR, APC, TP53 | LMNA 2949/4885MAPT 4/4885HTT 2198/4885 |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | LMNA 4592/4885MAPT 2563/4885HTT 712/4885 |
| US-20240067662-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | LMNA 3908/4885MAPT 3872/4885HTT 2804/4885 |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | LMNA 4587/4885MAPT 2304/4885HTT 499/4885 |
| US-20200181118-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | LMNA 3949/4885MAPT 3355/4885HTT 3486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.